Clinical Research Directory

Research on Aneurysm Growth Prediction in Vascular Dilation Caused by Bicuspid Aortic Valve Based on VDM and CFD

Bicuspid aortic valve (BAV) is the most common congenital valvular malformation, characterized by heterogeneous phenotypic subtypes that predispose patients to secondary aortic pathologies, including valvular dysfunction and ascending aortic dilation. With approximately 50% of BAV patients developing aortic dilation, a prevalence that continues to rise, accurate assessment of postoperative aortic remodeling remains a critical unmet clinical need for early risk stratification and optimized therapeutic decision-making. Currently, clinical surveillance relies heavily on periodic manual measurement of the maximum aortic diameter on follow-up computed tomography angiography (CTA), yet this approach suffers from several inherent limitations. It is a lagging indicator that detects irreversible wall damage only after significant enlargement has occurred. It oversimplifies complex three-dimensional morphological changes into a single linear dimension. It exhibits substantial intra- and inter-observer variability. It is also inefficient for large-scale longitudinal data management. Although alternative metrics such as computational fluid dynamics (CFD) derived hemodynamic parameters and morphological geometric features have been explored, existing methods remain constrained by static single-time-point analyses that fail to capture the dynamic biomechanical evolution driving aneurysm progression, high technical barriers that preclude routine clinical integration, and a lack of comprehensive models that systematically integrate dynamic deformation, static anatomy, and hemodynamic information. To address these gaps, this study aims to develop a fully automated, quantitative, and dynamic risk prediction system that leverages vascular deformation mapping (VDM) for noninvasive early detection of regional aortic deformation, integrates multiparameter features including dynamic deformational, static anatomical, and hemodynamic characteristics through an artificial intelligence model, and delivers intuitive structured reports to directly support clinical decision-making, thereby enabling earlier intervention and improved patient outcomes.

Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China

Safety, effectiveness and durability of Sapien 3 transcatheter aortic valve replacement in young aortic valve stenosis patients from China：A multi-center, retrospective and prospective, single arm, observational study

Cardiovascular Health Improvement Project

The goal of this project is to establish a biobank of clinical information, DNA, plasma, and aortic tissue samples from patients with cardiovascular disease as well as healthy controls.

Towards a More Standardized Bicuspid Aortic Valve Repair: Rationale and Design of CONTOUR Trial - a Randomized Trial

Background: Between one-third and one-half of patients with bicuspid aortic valve (BAV) disease develop significant aortic regurgitation (AR) at a young age, leading to cardiomyopathy and heart failure. Aortic valve repair is an evolving and still underused strategy in BAV patients with AR. The lack of sufficient standardization remains the main limitation of current repair techniques, resulting in an increased risk of AR recurrence and reoperation. The most controversial issue is the stabilization of the BAV annulus. The CONTOUR trial aims to compare two different BAV annuloplasty concepts in a prospective randomized study. Methods: CONTOUR is a multicenter, randomized controlled trial designed to enroll 100 consecutive BAV patients with AR across four sites in Germany. BAV AR patients with an asymmetric configuration and without concomitant root aneurysm will be randomized 1:1 to undergo aortic valve repair using an internal HAART 200 annuloplasty device (i.e., INTERNAL group) (n=50) or external annuloplasty (i.e., double external ring annuloplasty) in the EXTERNAL group (n=50). 4D flow MRI will be performed preoperatively (t1), postoperatively at discharge (t2), and at 1-year follow-up (t3) for rater-blinded assessment of hemodynamic profiles (i.e., flow eccentricity) and regurgitation fraction at the MRI core-lab. Two hierarchically ordered primary endpoints will be considered: (1) postoperative reduction of flow eccentricity at hospital discharge and (2) regurgitation fraction (%) at 1-year follow-up. Discussion: The CONTOUR trial is designed to test the hypothesis that an internal annuloplasty device, creating a completely symmetric post-repair BAV geometry, achieves superior aortic valve repair outcomes compared to external annuloplasty. If our hypothesis is confirmed, our study will significantly influence aortic valve repair practice and contribute to the refinement of guideline recommendations in the management of BAV patients with AR.

TAVR vs. SAVR Study of VitaFlow Liberty® for Severe BAV Stenosis

To evaluate the safety and effectiveness of the Transcatheter aortic valve and retrievable delivery system (VitaFlow Liberty®) for the treatment of severe bicuspid aortic valve (BAV) stenosis.

A Study of Chinese Congenital Bicuspid Aortic Valve

Pervious studies indicated that the prevalence of bicuspid aortic valve（BAV） might be higher in China. There is a familial predisposition to the development of BAV. The study analyzed epidemiological data on selected BAV and established a BAV cohort to observe disease progression and treatment outcomes.

Size Up Bicuspid With the LIra MEthod: the SUBLIME Study

Transcatheter aortic valve replacement (TAVR) outcomes in patients with raphe-type bicuspid aortic valve (BAV) are still suboptimal for the non negligible rate of stroke and permanent pacemaker implantation. There is still lack of consensus on the optimal sizing method for prosthesis selection in BAV patients. The objective of the present study is to evaluate the efficacy and safety of the LIRA sizing method in raphe-type BAV patients undergoing TAVR.